Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Exp Neurol. 2016 Nov 14;288:104–113. doi: 10.1016/j.expneurol.2016.11.010

Figure 2.

Figure 2

OXM dose- and time-dependently increases cell viabilities in human SH-SY5Y neuroblastoma cells and #9 cells. A and B, Both cells were treated with increasing concentrations (0, 10-9, 10-8, 10-7, 10-6 M) of OXM for either 24 h (A) or 48 h (B). MTS assays were used to assess cell viabilities at 24 h or 48 h after OXM treatment (statistical comparison vs. control value, *P < 0.05; **P <0.01; ***P < 0.001).